305 Results

People

  1. Seidman
    Seidman
  2. Aghajanian
    Aghajanian
  3. De Angelis
    De Angelis
  4. Hudis
    Hudis
  5. Kelsen
    Kelsen
  6. Lichtman
    Lichtman
  7. Saltz
    Saltz
  8. Scher
    Scher
  9. Bajorin
    Bajorin
  10. Fornier
    Fornier

Groups

  1. Department of Medicine (206)
  2. Solid Tumor Oncology Division (153)
  3. Survivorship Research (59)
  4. Hematologic Malignancies, Division of (51)
  5. Center for Hematologic Malignancies (47)
  6. Breast Medicine Service (43)
  7. Gastrointestinal Oncology Service (37)
  8. Surgery (29)
  9. Genitourinary Oncology Service (28)
  10. Center for Pancreatic Cancer Research (26)
  1. "peripheral neuropathy"
Formats
  1. Journal Article (283)
  2. Review (10)
  3. Conference Paper (6)
  4. Correspondence (3)
  5. Book Section (2)
  6. Guidelines (1)
Groups
  1. Department of Medicine (206)
  2. Solid Tumor Oncology Division (153)
  3. Survivorship Research (59)
  4. Hematologic Malignancies, Division of (51)
  5. Center for Hematologic Malignancies (47)
  6. Breast Medicine Service (43)

More Groups

People
  1. Andrew Seidman (16)
  2. Carol Aghajanian (12)
  3. Lisa De Angelis (12)
  4. Clifford Hudis (10)
  5. David Kelsen (10)
  6. Howard Scher (10)

More People

Years
  1. 2025 (9)
  2. 2024 (15)
  3. 2023 (19)
  4. 2022 (11)
  5. 2021 (7)
  6. 2020 (10)

More Years

Publications
  1. Journal of Clinical Oncology (26)
  2. Gynecologic Oncology (15)
  3. Lancet Oncology (14)
  4. Cancer (10)
  5. Annals of Oncology (9)
  6. Clinical Cancer Research (9)

More Publications

Publishers
  1. Elsevier Inc. (56)
  2. American Society of Clinical Oncology (26)
  3. Elsevier Science, Inc. (25)
  4. Springer (20)
  5. Wiley Blackwell (17)
  6. Oxford University Press (15)

More Publishers

Results (305)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: An open-label, multicentre, phase 1b study
    Journal Article

    O'Hara, M. H.; O'Reilly, E. M.; Varadhachary, G.; Wolff, R. A.; Wainberg, Z. A.; Ko, A. H.; Fisher, G.; Rahma, O.; Lyman, J. P.; Cabanski, C. R.; more...
    Lancet Oncology (2021)

    Fulltext@MSK | Save
  • Patient preferences for first-line treatment of classical Hodgkin lymphoma: A US survey and discrete choice experiment
    Journal Article

    Khan, N.; Feliciano, J.; Müller, K.; He, M.; Tao, R.; Korol, E.; Dalal, M.; Rebeira, M.; Matasar, M.
    Leukemia and Lymphoma (2020)

    Fulltext@MSK | Save
  • Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): Results from a randomised, multicentre, open-label, phase 3 study
    Journal Article

    Dimopoulos, M.; Quach, H.; Mateos, M. V.; Landgren, O.; Leleu, X.; Siegel, D.; Weisel, K.; Yang, H.; Klippel, Z.; Zahlten-Kumeli, A.; more...
    Lancet (2020)

    Fulltext@MSK | Save
  • The emerging role of antibody-drug conjugates in urothelial carcinoma
    Review

    Lattanzi, M.; Rosenberg, J. E.
    Expert Review of Anticancer Therapy (2020)

    Fulltext@MSK | Save
  • Consensus recommendations for management and counseling of adverse events associated with lorlatinib: A guide for healthcare practitioners
    Guidelines

    Reed, M.; Rosales, A. L. S.; Chioda, M. D.; Parker, L.; Devgan, G.; Kettle, J.
    Advances in Therapy (2020)

    Fulltext@MSK | Save
  • Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma
    Journal Article

    Noel, M.; O’Reilly, E. M.; Wolpin, B. M.; Ryan, D. P.; Bullock, A. J.; Britten, C. D.; Linehan, D. C.; Belt, B. A.; Gamelin, E. C.; Ganguly, B.; more...
    Investigational New Drugs (2020)

    Fulltext@MSK | Save
  • A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer
    Journal Article

    Cadoo, K. A.; Grisham, R. N.; O'Cearbhaill, R. E.; Boucicaut, N. N.; Henson, M.; Iasonos, A.; Zhou, Q.; Sarasohn, D. M.; Gallagher, J.; Kravetz, S.; more...
    Gynecologic Oncology (2020)

    Fulltext@MSK | Save
  • Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: Integrated analysis of three phase 1-2 trials
    Journal Article

    Drilon, A.; Siena, S.; Dziadziuszko, R.; Barlesi, F.; Krebs, M. G.; Shaw, A. T.; de Braud, F.; Rolfo, C.; Ahn, M. J.; Wolf, J.; more...
    Lancet Oncology (2020)

    Fulltext@MSK | Save
  • Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: Integrated analysis of three phase 1-2 trials
    Journal Article

    Doebele, R. C.; Drilon, A.; Paz-Ares, L.; Siena, S.; Shaw, A. T.; Farago, A. F.; Blakely, C. M.; Seto, T.; Cho, B. C.; Tosi, D.; more...
    Lancet Oncology (2020)

    Fulltext@MSK | Save
  • Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: A subgroup analysis of the phase 3 KEYNOTE-045 trial
    Journal Article

    Nishiyama, H.; Yamamoto, Y.; Sassa, N.; Nishimura, K.; Fujimoto, K.; Fukasawa, S.; Yokoyama, M.; Enokida, H.; Takahashi, K.; Tanaka, Y.; more...
    International Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save